HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial.

AbstractOBJECTIVE:
Elevated levels of tumor necrosis factor alpha (TNFalpha) have been identified in the synovium of patients with reactive and undifferentiated arthritis, implicating TNFalpha in the pathogenesis of these disorders. This finding has provided a rationale for the use of TNFalpha antagonists in the treatment of reactive arthritis; however, the possibility that the triggering microorganism might persist in affected joints and become activated with use of these agents has been of concern.
METHODS:
The efficacy and safety of etanercept (25 mg subcutaneous twice weekly) in 16 patients with undifferentiated or reactive arthritis was assessed in a 6-month open-label trial. Synovial biopsies were performed before and after treatment with etanercept. Polymerase chain reaction (PCR) analysis was performed on the synovial biopsy samples to evaluate for the presence of nucleic acid material of bacterial organisms. Outcome measures including tender and swollen joint counts, pain assessment on a 10-point visual analog scale, and functional ability as measured by the Health Assessment Questionnaire were determined before and after etanercept therapy.
RESULTS:
Ten of 16 patients completed the trial. Six patients withdrew, but none had a worsening of arthritis or infection. Of the 10 completers, 9 could be classified as treatment responders, despite the evidence of bacterial organisms on PCR analysis prior to initiating etanercept in 3 patients; 2 patients became PCR negative on etanercept. Five of 6 patients with adequate synovial biopsy specimens showed improvement, but not normalization of histology.
CONCLUSION:
Etanercept was well-tolerated without clinical exacerbation of any suspected underlying infections and appeared to provide therapeutic benefit in our cohort of patients with reactive and undifferentiated arthritis.
AuthorsStephanie D Flagg, Robert Meador, Elizabeth Hsia, Tasanee Kitumnuaypong, H Ralph Schumacher Jr
JournalArthritis and rheumatism (Arthritis Rheum) Vol. 53 Issue 4 Pg. 613-7 (Aug 15 2005) ISSN: 0004-3591 [Print] United States
PMID16082643 (Publication Type: Journal Article)
Chemical References
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Etanercept
Topics
  • Adolescent
  • Adult
  • Aged
  • Antirheumatic Agents (administration & dosage, therapeutic use)
  • Arthritis (drug therapy, physiopathology)
  • Arthritis, Reactive (drug therapy, physiopathology)
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G (administration & dosage, therapeutic use)
  • Male
  • Middle Aged
  • Pain (physiopathology)
  • Polymerase Chain Reaction
  • Receptors, Tumor Necrosis Factor (administration & dosage, therapeutic use)
  • Synovitis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: